Stockscreener 앱 받기
35.65
1.05%
0.37
시간 외 거래:
35.65
전일 마감가:
$35.28
열려 있는:
$35.68
하루 거래량:
1.04M
Relative Volume:
1.08
시가총액:
$2.80B
수익:
$866.00K
순이익/손실:
$-283.65M
주가수익비율:
-8.3548
EPS:
-4.267
순현금흐름:
$-226.25M
1주 성능:
+0.65%
1개월 성능:
+1.11%
6개월 성능:
+35.91%
1년 성능:
+52.68%
1일 변동 폭
$35.12
$36.40
1주일 범위
$33.37
$36.40
52주 변동 폭
$19.72
$40.30
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
35.65 | 2.77B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 업그레이드 | Barclays | Underweight → Overweight |
| 2026-03-23 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-13 | 개시 | Barclays | Underweight |
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Celldex Therapeutics Inc (CLDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts (NASDAQ:CLDX) - Seeking Alpha
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics, Inc. Revenue Breakdown – DUS:TCE2 - TradingView
CLDX|Celldex Therapeutics Inc|Price:35.280|Chg%:-0.140 - TradingKey
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year? - Yahoo Finance
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run - Sahm
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $40 to $70 - Moomoo
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF) - The Globe and Mail
CELLDEX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $70 FROM $78 - webull.com
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial DiscontinuationSlideshow (NASDAQ:CLDX) 2026-07-22 - Seeking Alpha
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study - BioPharma Dive
Drum KIT: Celldex CSU rhythm still on post-barzo PN phase II - BioWorld News
Stifel Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $68 - Moomoo
Celldex cuts price target after halting Phase 2 trial for key drug due to efficacy failure. - Pluang
Celldex Stands By Barzolvolimab in CSU After Prurigo Nodularis Miss - insights.citeline.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
Canaccord cuts Celldex stock price target after trial miss By Investing.com - Investing.com Canada
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study - Benzinga
Celldex scraps antibody in itchy skin nodules after Phase 2 flop - Endpoints News
Celldex drops Phase II study of barzolvolimab in prurigo nodularis - The Pharma Letter
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss - Yahoo Finance
Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating - marketscreener.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
CLDX Stock Down 10% After-Hours — What’s Driving The Selloff? - Yahoo Finance
Celldex discontinues prurigo nodularis trial after phase 2 miss - Investing.com
Celldex stock falls after phase 2 trial misses key endpoints By Investing.com - Investing.com Canada
Celldex discontinues prurigo nodularis trial after phase 2 miss By Investing.com - Investing.com Canada
Celldex stock falls after phase 2 trial misses key endpoints - Investing.com
Celldex Drug Depleted Mast Cells but Did Not Ease PN Itch - Stock Titan
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Biotech Gem with 64% Potential Upside - DirectorsTalk Interviews
Guggenheim raises Celldex stock price target on trial outlook By Investing.com - Investing.com Canada
MSN Money - msn.com
Celldex Therapeutics, Inc. Announces Retirement of Sam Martin from Senior Vice President, Effective on or About March 31, 2027 - marketscreener.com
Celldex Therapeutics, Inc. Announces Retirement of Sam Martin as Chief Financial Officer, Effective on or About March 31, 2027 - marketscreener.com
Celldex Therapeutics CFO Plans to Retire in 2027 - marketscreener.com
Celldex CFO Sam Martin to retire in March 2027 By Investing.com - Investing.com Canada
Celldex CFO Sam Martin to Retire; Company Begins Search for Successor - TradingView
Celldex CFO Sam Martin to retire in March 2027 - Investing.com
Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027 - Stock Titan
Celldex Starts CFO Search as Martin Plans 2027 Retirement - Stock Titan
Press Release: Celldex Announces Planned Transition of Chief Financial Officer - Moomoo
Celldex Therapeutics (CLDX) Gets Fresh Index Attention As Valuation Debate Heats Up - simplywall.st
Celldex Therapeutics stock hits 52-week high at 39.16 USD By Investing.com - Investing.com Nigeria
Celldex Therapeutics stock hits 52-week high at 39.16 USD - Investing.com
Price to sales forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Price to book forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed? - Sahm
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):